ArticleRSC advances2018
Polypeptide - decorated nanoliposomes as novel delivery systems for lutein.
Article in RSC advances, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 43 citations in OpenAlex.
- Bixin Beyond Colour: Expanding Therapeutic Horizons Through the Integration of Pharmacological Potential with Modern Drug Design and Delivery Strategies.Drug design, development and therapy · 2026Review
- Nanoliposomes for the Delivery of Food Bioactive Compounds: Preparation, Characterization, and Application in Precision Nutrition.Chemistry & biodiversity · 2026Review
- Comparative Pharmacokinetics of Lutein and Zeaxanthin from Phospholipid, Liposomal, and MCT Formulations in SD Rats.Pharmaceutics · 2025Article
- Assessment of a Functional Yogurt Enriched with Anthocyanin-Loaded Nanoliposomes: Sensory Evaluation and Physicochemical Stability During Cold Storage.International journal of molecular sciences · 2025Article
- Innovative PEGylated chitosan nanocarriers for co-delivery of doxorubicin and CpG in breast cancer therapy: Preparation, characterization, and immunotherapeutic potential.Medical oncology (Northwood, London, England) · 2025Article
- Exploring the Antitumor Efficacy of PEGylated Liposomes Loaded with Licorice Extract for Cancer Therapy.Current cancer drug targets · 2025Article
- Physical Properties of Cellulose Derivative-Based Edible Films Elaborated with Liposomes Encapsulating Grape Seed Tannins.Antioxidants (Basel, Switzerland) · 2024Article
- Developing Engineered Nano-Immunopotentiators for the Stimulation of Dendritic Cells and Inhibition and Prevention of Melanoma.Pharmaceutical research · 2024Article
- New Healthy Low-Sugar and Carotenoid-Enriched/High-Antioxidant Beverage: Study of Optimization and Physicochemical Properties.Foods (Basel, Switzerland) · 2023Article
- Impact of PEGylated Liposomal Doxorubicin and Carboplatin Combination on Glioblastoma.Pharmaceutics · 2022Article
- Nanoscale Delivery Systems of Lutein: An Updated Review from a Pharmaceutical Perspective.Pharmaceutics · 2022Review
- A PEGylated Nanostructured Lipid Carrier for Enhanced Oral Delivery of Antibiotics.Pharmaceutics · 2022Article
- β-Lactoglobulin-Modified Mesoporous Silica Nanoparticles: A Promising Carrier for the Targeted Delivery of Fenbendazole into Prostate Cancer Cells.Pharmaceutics · 2022Article
- PEGylated Mesoporous Silica Nanoparticles (MCM-41): A Promising Carrier for the Targeted Delivery of Fenbendazole into Prostrate Cancer Cells.Pharmaceutics · 2021Article
- Recent Advances on Nanoparticle Based Strategies for Improving Carotenoid Stability and Biological Activity.Antioxidants (Basel, Switzerland) · 2021Review
- Critical Review of Lipid-Based Nanoparticles as Carriers of Neuroprotective Drugs and Extracts.Nanomaterials (Basel, Switzerland) · 2021Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lutein (LUT) is a bioactive food compound found in various vegetables and plays a critical role in the promotion of health and well-being. However, lutein is an unstable molecule which has a very low bioavailability caused by its poor solubility in aqueous media, and is poorly absorbed when administered orally. To enhance the stability, release and bioactivity of lutein, poly-l-lysine (PLL) decorated nanoliposomes (PLL-LUT-NLP) were developed as novel delivery systems for lutein. The mean particle size of PLL-LUT-NLP was found to be in the range 264-367 nm with a low polydispersity index (PDI < 0.4). The zeta potential changed from -38.6 mV in undecorated nanoliposomes to -27.9 mV in PLL-decorated nanoliposomes. Furthermore, the lutein entrapment efficiency (EE%) of PLL-LUT-NLP was found to be highest in nanoliposomes decorated with 0.06% (w/v) PLL. PLL could protect lutein in nanoliposomes from degradation and promote the lutein release from the nanoliposomes in gastrointestinal fluid conditions. Additionally, the PLL-decorated nanoliposomes maintained the antioxidant activity of the lutein, and the antiproliferative activity was more significant than that of undecorated nanoliposomes in inhibiting the proliferation of human tumor cells. These results suggest that PLL-decorated nanoliposomes have potential to be used for efficient delivery of lutein and further improve its bioavailability.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.